Major Article submitted to *Journal of Infectious Diseases*:

Regional differences in vaccine uptake and serological responses to vaccine and circulating strains of H1N1 viruses among patients with confirmed influenza

Ashley L. Fink¹, Hsuan Liu¹, Kathryn Shaw-Saliba^{1,2}, Thomas Mehoke³, Jared Evans³, Zhen-Ying Liu⁴, Mitra Lewis², Lauren Sauer², Peter Thielen³, Kuan-Fu Chen⁴, Richard Rothman², Sabra L. Klein^{1,5,6,*}, Andrew Pekosz^{1, 2, 7,*}

¹W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 USA;

²Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 USA;

³Research and Exploratory Development Department, Johns Hopkins Applied Physics Laboratory, Laurel, Maryland 20723 USA;

⁴Department of Emergency Medicine, Clinical Informatics and Medical Statistics Research Center, Keelung Chang Gung Memorial Hospital, Chang Gung University, Keelung and Taoyuan City, 33302 Taiwan;

⁵Department of Biochemistry and Molecular Biology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 USA;

⁶Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 USA;

⁷Department of Environmental Health and Engineering, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205 USA.

Running title: Antibodies to H1N1 influenza viruses (40 characters max)

Key Words: H1N1 influenza, human surveillance, neutralizing antibody, seasonal influenza vaccine

Manuscript statistics:

Abstract:

Text: 3500 max (currently 3500)

Number of figures: 4 (7 tables and figures max; 4 panels per figure)

Number of tables: 3 (can have up to 25 MB of online suppl info)

References:

Financial support: This work was supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contracts HHS N272201400007C and HHS N272201400006C.

Disclosures: The authors report no conflicts of interest

*Correspondence:

Sabra L. Klein, Ph.D., sklein2@jhu.edu, 410-955-8898

Andrew Pekosz, Ph.D., apekosz1@jhu.edu, 410-502-9306

Background. Seasonal epidemics of influenza are often characterized through national or international surveillance efforts to determine vaccine efficacy and vaccine strain selection, but they do not provide detailed information about local variations in factors that can influence influenza cases and disease severity.

Methods. Surveillance for influenza like illness was performed in Emergency Medicine Departments in Taipei, Taiwan and Baltimore, Maryland during the winter of 2015-16. Detailed demographic and clinical data were obtained. Nasal swabs or washes were collected for influenza virus diagnosis, sequencing and isolation. Serum was collected to determine neutralizing antibody levels.

Results. H1N1 viruses dominated both sites, but more influenza cases occurred in Taipei compared to Baltimore. H1 HA clade diversity was greater in Taipei. Vaccination rates were lower in Taipei than Baltimore, but vaccination was associated with an increase in serum neutralizing antibodies to recent H1N1 strains in Taipei, but not Baltimore. There was a higher level of preexisting immunity to circulating H1N1 strains in Baltimore.

Conclusions. Regional differences in preexisting immunity and H1N1 strain circulation may have contributed to the vastly different 2015-16 influenza seasons in Taipei and Baltimore and suggest immune responses to vaccination can be affected by the degree of preexisting immunity in the population.

Influenza causes disease in the human population and the specific strain of virus that is circulating, the levels of preexisting immunity to circulating viruses, vaccine uptake, vaccine strain match to circulating virus strains, and the presence of mutations that modulate virus fitness all contribute to the magnitude of seasonal cases and disease severity [1, 2]. Other factors impact the susceptibility to influenza in a strain independent manner, including age, immune status, pregnancy, gender, and the presence of co-morbidities [2-4].

The 2015-16 influenza season in the Northern hemisphere was dominated by H1N1 Influenza A virus, with significant differences in the number of cases and disease severity across different countries [5]. In contrast, East and Southeast Asia experienced a particularly strong influenza season [5]. Serological assays using ferret antiserum indicated circulating H1N1 viruses were antigenically similar to the 2015-16 vaccine strain [6-9]. Surveillance for influenza-like illness (ILI) in 2015-16 was performed in the Emergency Departments (ED) of Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan and the Johns Hopkins Medical Institution (JHMI), Baltimore, Maryland. The influenza season in Taipei was more severe than in Baltimore and factors including differences in circulating virus strains, vaccination rates, serum neutralizing antibody levels after vaccination, antibody cross reactivity between vaccine and circulating strains, and levels of preexisting immunity contributed to the different influenza seasons at the two surveillance sites.

Materials and Methods

Human sample collection and ethics

The human subjects protocol was reviewed and approved by the JHMI Institutional Review Board (IRB) and the CGMH IRB (IRB00052743). This protocol allowed for the enrollment of influenza positive, negative, and asymptomatic patients from the JHMI and CGMH ED with informed consent. For each patient, nasal pharyngeal (NP) swab or nasal wash (NW) and 10 ml of blood were collected at enrollment (i.e., time of presentation and positive influenza test, ≤ 7 days after the onset of symptoms). NP swabs were tested for influenza A virus using the CepheidGeneExpert© test. Blood was collected in Vacutainer tubes (BD), serum was separated and stored at -70°C . The patient's basic demographics (i.e., age, ethnicity, race, gender, co-morbidities, and medications) were collected using data collection forms. Disease severity data (i.e., use of oxygen, hospital admission, disease outcomes) were collected during a follow up conversation and by chart review. For vaccination status, patients were asked if they received an influenza vaccine for the current season (2015-2016).

Virus sequencing and phylogenetic analysis

Viral RNA isolation and sequencing was performed as previously described [10, 11] and the phylogenetic analysis was performed as previously described [12] by comparing the full-length nucleotide sequence of the hemagglutinin (HA) open reading frame from representative strains of all clades of H1N1 2009 pandemic viruses retrieved from the Global initiative on sharing all influenza data (GISAID). Trees were viewed and colored using FigTree and HA clades were identified by adding known clade references to these trees and identifying branches for the 6B, 6B.1, and 6B.2 clades. Clade 6B.1 was

defined by HA1 amino acid substitutions S84N, S162N and I216T; and clade 6B.2 was defined by HA1 amino acid substitutions V152T and V173I and HA2 amino acid substitutions E164G and D174E. Sequences generated in the study were submitted to GenBank NCBI Influenza Virus Database (**Supplementary Table 1**).

Cell cultures

Madin-Darby canine kidney (MDCK) cells were used to grow all viruses and were cultured in Dulbecco's modified Eagle medium (DMEM; Sigma) with 10% fetal bovine serum (Gibco), 100 µg/ml of penicillin and 100 µg/ml of streptomycin (Quality Biological), and Glutamax (Gibco) at 37°C and 5% CO₂. Human nasal epithelial cell (hNEC) cultures were isolated from non-diseased tissue after endoscopic sinus surgery for non-infection related conditions and grown at air-liquid interface (ALI). The hNEC isolation, differentiation and culture conditions have been described in detail previously [13].

Vaccine viruses

A recombinant influenza virus encoding the HA protein derived from the sequence of A/Michigan/45/2015-like egg-adapted virus (A/Mich/45/15; GISAID Accession no.: EPI685579) was used as the A/Mich/45/15 vaccine virus for serology assays. The HA protein has an egg-adapted mutation at position 223 (glutamine (Q) to arginine (R); Q223R) on the HA protein. A/Mich/45/15 virus was generated using a 12-plasmid influenza reverse genetic system [14, 15] with plasmids encoding the HA and the

neuraminidase (NA) of the A/Mich/45/15-like virus and the remaining 6 viral gene segments derived from A/California/7/2009 (A/Cal/7/09) as described previously [16].

Viral isolates from clinical samples used for serology and growth analysis

Fluids from NP swabs or NW from influenza A virus positive individuals were used to isolate viruses by inoculating primary, differentiated hNEC cultures as previously described [12]. A representative viral isolate from each clade was used for serology assays and growth analysis on hNECs. The representative viral isolates used, include: A/Baltimore/0026/2016 (JHMI 6B.1), A/Linkou/0032/2015 (CGMH 6B.1), A/Linkou/0029/2015 (CGMH 6B.2), and A/Linkou/0030/2015 (CGMH 6B).

Virus growth curves and TCID₅₀ assay

Low-multiplicity of infection (MOI) growth curves were performed in quadruplicate by infecting hNECs in 24-well Transwell© inserts at an approximate MOI of 0.1 50% tissue culture infectious units (TCID₅₀) per cell as described previously [15, 16].

Ferret antisera

Ferrets (male, Triple F Farms, Sayre, PA) were lightly anesthetized with isoflurane and intranasally inoculated with 10⁶ TCID₅₀ in 1 ml PBS of A/Baltimore/0026/2016 (6B.1) (two ferrets) or A/Linkou/0029/2015 (6B.2) (two ferrets). After 21 days, animals were sacrificed to obtain sera. Animal experiments were approved by the St. Jude Children's Research Hospital Animal Care and Use Committee.

Serum neutralization assay

Human or ferret serum was used in microneutralization assays using MDCK cells as previously described [10]. The neutralizing antibody titer was calculated as the highest serum dilution that eliminated virus cytopathic effects in 50% of the wells.

Statistical analysis

Serology data were analyzed with a 2-way ANOVA followed by pairwise multiple comparisons or by 1-way ANOVA or students t-test. Fold change in antibody titers between different virus strains and across different sites were analyzed by Chi-square analysis. Virus replication kinetics were analyzed using a repeated measures 2-way ANOVA. Clinical data in tables 1-3 were analyzed by Chi-square analysis.

For multivariate analyses, the antibody titers were log transformed. All variables with $p < 0.2$ and beta coefficient > 0.1 in the bivariate linear regression were evaluated with multivariate linear regression with Allen-Cady backward selection procedure, with priority determined by clinical relevance and existing literature support. We adopted the Akaike's Information Criteria and the Chi-square goodness of fit test to evaluate the model fitness. Interaction check was performed to evaluate the potential effect modification between vaccination, antibody titers, and significant risk factors. Because of the relative small sample size, we further performed propensity score weighting modeling, in order to simultaneously adjust multiple confounders. Confounders considered to influence the causal relationship between vaccination and antibody titers were modeled to generate the propensity of vaccination, with the propensity score used

as the weight to balance the potential confounding and evaluate the average treatment effect. Mean differences were considered statistically significant if $p < 0.05$.

Results

Influenza surveillance was performed in the ED at JHMI and at CGMH from November 1, 2015 (week 44 of 2015) to April 30, 2016 (week 17 of 2016). The basic demographic and disease characteristics of patients reporting with ILI that were either confirmed to be infected (IAV+) or not (IAV-) in Baltimore (n=252) and in Taipei (n=245) are summarized in **Table 1**. In Baltimore, there was a racial difference, in which more Caucasian/white patients with ILI were IAV- (40.1%) than IAV+ (23.5%). For IAV vaccination in Baltimore, 50.3% of IAV- patients received the 2015-16 seasonal vaccine compared to 29.8% in the IAV+ group. The Baltimore IAV- population had significantly more patients with multiple co-morbidities (50.3%) than the IAV+ population (35.3%). There was also a greater number of IAV- patients with ILI admitted to JHMI hospitals (44.3%) than IAV+ patients (29.4%). In contrast, fewer differences were observed between the IAV+ and IAV- individuals with ILI from the Taipei population. Greater numbers of females as compared to males were present in the IAV+ group (65.5%) than the IAV- group (52.6%) in Taipei.

Enrollment weeks for IAV+ individuals were plotted (**Figure 1A and 1B**). Influenza A virus activity was lower and peaked later (mid-March; **Figure 1A**) in the Baltimore population and was higher and peaked earlier (January-February; **Figure 1B**) in the

Taipei population which was representative of the overall IAV activity in each country [6, 7].

Among the 233 IAV+ cases across the surveillance sites, 111 NW or NP swabs were processed for sequencing. H1N1 was the predominant IAV subtype circulating globally [6, 17, 18] and in both Baltimore and Taipei (**Figure 1A and 1B**). One-hundred and three of the isolates (92.8%) were identified as H1N1 viruses and only 8 (7.2%) were H3N2 viruses. Seventy-nine of the 103 H1N1 clinical virus isolates yielded sufficient coverage of the HA segment and all belonged to clade 6 subgroup B (clade 6B), 6B.1 or 6b.2 [19], with the latter two clades newly emerged in this season [20]. Phylogenetic analysis of the HA gene sequences from patients in Baltimore (red) or Taipei (blue) classified most isolates as clade 6B.1. Clade 6B.2 viruses made up a significant number of the isolates in Taipei, but were absent in Baltimore (**Figure 2A and 2B**).

A comparison of the patient populations of Baltimore and Taipei that were infected with H1N1 viruses revealed that these populations were similar in terms of demographics and disease severity (**Table 2**), with expected differences in race observed between sites. More patients with no known co-morbidities for severe influenza were infected in the Taipei population compared to Baltimore. Vaccine coverage was higher in the Baltimore population (31.6%) than the Taipei population (4.7%). These data show stronger influenza activity and H1N1 infection in Taipei compared to Baltimore.

Outside of race, there were no differences in the clinical or demographic characteristics of patients infected with clade 6B.1 viruses in Baltimore when compared to those infected with 6B.1 viruses in Taipei (**Supplementary Table 2**). Among patients infected with clade 6B.1 viruses at the two sites, there were no significant demographic differences. Likewise, there were no differences in Taipei patients infected with 6B.1 compared to 6B.2 viruses (**Supplementary Table 2**), indicating that the disease incidence and severity differences between the Baltimore and Taipei sites were not driven by any specific demographic or clinical factor.

The amino acid mutations in the HA protein of circulating virus strains were mapped on the H1 HA protein crystal structure (**Figure 2C**). Clade 6B.1 viruses were characterized by mutations S84N, S162N, and I216T (purple), with an amino acid residue 162 on the Sa antigenic site (blue). Amino acid 216, along the 220 loop of the receptor-binding domain was adjacent to the Sb antigenic site (pink). The I216T mutation may be a compensatory mutation as a result of the S162N mutation [21]. Clade 6B.2 viruses contained two HA1 mutations: V152T, adjacent to the Sa and Sb antigenic sites and V173I, near the Ca1 antigenic site (yellow). In addition to the mutations in HA1, 6B.2 viruses contained two mutations in HA2: E164G and D174E which were both on the surface of the HA stalk domain (**Figure 2C**). When compared to the vaccine strain A/Ca/7/09, both clade 6B.1 and 6B.2 viruses had 11 additional amino acid mutations (P83S, D97N, K163Q, S185T, S203T, A256T, K283E, I321V and HA2: E47K, S124N, and E172K), many of which were located on or near antigenic sites.

The replication efficiency of 6B.1 and 6B.2 clinical virus isolates was assessed using hNEC cultures. No significant differences in virus replication kinetics were detected (**Figure 2D**) with viruses isolated from the two surveillance sites.

Influenza-specific antibodies are considered the primary correlate of protection against influenza infection in humans [22]. Neutralizing antibody responses to the clade 6B.1 virus were greater in patients from Baltimore than Taipei in serum collected at the time of enrollment (**Figure 3A**). The higher titer of anti-clade 6B.1 antibodies, but not antibodies to the vaccine strain, in the Baltimore population indicated higher titers of antibodies to circulating viruses that do not cross react with the vaccine strain and suggested that human antibodies can differentiate between the H1N1 circulating and vaccine strains.

We compared individuals that received the 2015-16 seasonal influenza vaccine with those that did not across the two surveillance sites. Although receipt of the seasonal vaccine did not affect neutralizing antibody responses to the vaccine or circulating viruses in patients from Baltimore (**Figure 3B**), neutralizing antibody responses from Taipei patients were significantly greater in vaccinated compared to unvaccinated patients (**Figure 3C**). We conclude that geographic location and presumably the history of exposure to circulating and vaccine strains of influenza impact the antibody response induced by vaccination.

The H1N1 component of the seasonal influenza vaccine was updated for the 2017-18 influenza season from A/Cal/7/09 to clade 6B.1 A/Mich/45/15 [23], so we hypothesized that the baseline neutralizing antibody responses to this virus would be similar to responses to the 2015-16 circulating clade 6B.1 viruses. Both vaccinated and unvaccinated patients from Baltimore had cross-reactive neutralizing antibody responses to the A/Mich/45/15 vaccine virus, whereas in Taipei only vaccinated individuals had cross-reactive neutralizing antibody responses as compared to unvaccinated individuals (**Figure 4A**), indicating that vaccination could have regional differences in the induction of cross-reactive antibody responses.

We analyzed the baseline neutralizing antibody titers to the A/Cal/7/09 and the A/Mich/45/15 vaccine strain. The serum cross-reactivity to the A/Mich/45/15 vaccine virus as compared to the A/Cal/7/09 vaccine virus was greater in Baltimore compared Taipei using a ≥ 4 fold increase in titer as a cutoff (**Figure 4B**) which was driven by differences among unvaccinated patients at the two surveillance sites. Using a more stringent cutoff of ≥ 8 fold increase in titer, there was still greater recognition of the A/Mich/45/15 vaccine virus among patients from Baltimore as compared to those from Taipei, with both unvaccinated and vaccinated populations driving the cross-site differences (**Figure 4B**), indicating there are regional differences in the recognition of vaccine strains and the circulating 6B.1 viruses (**Figure 3A and 4A**).

The antigenic characterization of IAV isolates is traditionally measured in HAI assays using strain specific, post-infection ferret antisera [24] and HAI assays showed ferret

sera raised to circulating reference 6B.1 and 6B.2 viruses cross-reacted well with the A/Cal/7/09 vaccine virus [19]. Using sera from ferrets infected with the circulating H1N1 virus strains from Baltimore and Taipei, there were greater neutralizing antibody responses to the clade 6B virus as compared with the A/Cal/7/09 vaccine virus (**Figure 4C**). All ferrets had a ≥ 4 fold increase in titer specific to each of the circulating virus strains as compared to the A/Cal/7/09 vaccine strain (**Figure 4D**). Our data showed low cross-reactivity between the ferret sera raised to circulating H1N1 strains and the A/Cal/7/09 vaccine strain, indicating potential antigenic differences between the circulating and vaccine strains, and supporting the recommendation to update the H1N1 component of the seasonal influenza vaccine.

Using an Allen-Cady modified stepwise multivariable regression model to control for confounding variables revealed increased age was consistently associated with lower titers (**Table 3**). In contrast, a significant association between age and neutralizing antibody titers in our univariate analysis was not observed (**Supplementary Figure 1**). Other factors that were associated with lower titers in different clades included male gender (A/Cal/7/09, 6B.1), steroid usage (6B), higher BMI (6B.2), being Asian (6B.1), and some socioeconomic factors. Although we did not observe gender differences in baseline neutralizing antibody titers in our univariate analysis (**Supplementary Figure 2**), previous studies have established that males tend to have significantly lower neutralizing antibody titers to influenza as compared with females [25]. Receipt of the influenza vaccine was associated with higher baseline neutralizing antibody titers to the A/Cal/7/09 vaccine strain virus and the clade 6B and 6B.2 circulating viruses. In a

propensity score weighting model, receipt of the influenza vaccine resulted in higher neutralizing antibody titers to all viruses except the clade 6B.1 virus. In the multivariable regression, when the variable “Asian” was removed, vaccination was still significantly associated with higher baseline neutralizing antibody titers, indicating that there could be a confounding effect between being Asian and receipt of the influenza vaccine. In the effect modification multivariable regression analysis, we found that vaccinated patients from Taipei had consistently higher antibody titers across different clades, except 6B.2 (**Table 3**). The observation that receipt of the influenza vaccine was associated with higher baseline neutralizing antibody titers to all viruses except the clade 6B.1 virus further confirms the recommendation to update the H1N1 vaccine virus to A/Mich/45/15, which is a clade 6B.1 virus.

Discussion

This study illustrates differences in influenza activity, pre-existing influenza immunity, and virus strain circulation in the 2015-16 influenza season across surveillance sites located in Baltimore, Maryland and Taipei, Taiwan. We conclude that regional factors as well as host demographic variables, including age, gender, and BMI, may play important roles in modulating receipt of seasonal influenza vaccines, vaccine-induced immunity, and severity of influenza disease.

The 2015-16 influenza season was characterized by increased H1N1 influenza cases in Taipei compared to Baltimore, with differences in the HA clades that circulated at each site, consistent with previous reports [26-28]. Clade 6B.2 viruses circulated in primarily

in Asia but never became a common clade globally. While specific amino acid changes near antigenic sites are present in clade 6B.2 viruses, they appear to be antigenically indistinguishable from clade 6B.1 viruses using human and ferret serum. Both H1N1 clades had similar replication kinetics in hNEC cultures, indicating there were no inherent differences in virus fitness between the two clades. Since the 2016-17 season, only H1N1 6B.1 viruses have been detected and have evolved to different clade 6B.1 subclades which are continuing circulation worldwide [23, 29-32].

The demographic characteristics of the Baltimore and Taipei sites were similar, except for race. It is difficult to ascertain the contribution of race to influenza susceptibility given these differences. There was a significantly larger number of influenza cases in individuals with no known influenza co-morbidities in Taipei compared to Baltimore, indicating a greater degree of susceptibility in the population in Taipei, which is supported by the overall lower vaccine rate and levels of neutralizing antibodies to circulating human H1N1 present in that population. The overall lower antibody titers to 6B.1 viruses in Taipei were surprising given that antigenically related viruses have been circulating globally since 2009. Vaccination, however, did not affect neutralizing antibody titers in patients from Baltimore, perhaps due to higher levels of preexisting H1N1 immunity in that population. These data suggest that regional differences in influenza vaccine uptake and immune responses to vaccination are present and can impact the overall susceptibility of the population to influenza virus infection.

Global 2015-16 influenza surveillance in most countries indicated the circulating H1N1 viruses were antigenically similar to the vaccine A/Cal/7/09 [6-9, 17, 33, 34]. In our study, antigenic differences between the H1N1 vaccine strain and circulating viruses in 2015-16 were detected using human serum and serum from ferrets infected with circulating H1N1 viruses in neutralization assays. Consistent with those observations, higher neutralizing antibody responses to the A/Mich/45/15 vaccine strain compared to the A/Cal/7/09 vaccine strain were detected. Studies also showed that humans elicited differential antibodies recognizing cell-derived or egg-adapted vaccines which was driven by the egg-adaption mutation Q226R (which is Q223R in H1 numbering) of A/Cal/7/09, thus causing some individuals to better recognize the vaccine strain in HAI assays [35-37]. However, we did not see significant differences in neutralization titers of 6B.1 circulating virus compared to the A/Mich/45/15 vaccine containing Q223R (Figure 3A 6B.1 and Figure 4A). Even though ferret antiserum were unable to distinguish between A/Cal/7/09 and A/Mich/45/15, the WHO changed the H1N1 vaccine component to A/Mich/45/15 in the 2017 Southern hemisphere vaccine and subsequently in the 2017-18 Northern hemisphere because circulating viruses were poorly recognized by some post-vaccination adult human serum [38, 39]. Our use of human sera and virus neutralization assays strongly indicate antigenic differences between the vaccine and circulating strains.

We did not observe any relationship between neutralizing antibody titers and specific age-ranges [40-43], but this is most likely due to small sample sizes in most age groups. Although more females presented as IAV+, at least in Taipei, male gender, steroid use,

and higher BMI correlated with lower neutralizing titers, as these are associated with an impaired humoral immune response [44, 45].

There are limitations of this study. Our acute influenza detection protocol does not include pediatric patients so we are unable to assess preexisting immunity and case numbers in age groups <18 years of age. Because only one surveillance site is used in each country, we are unable to capture any regional differences within the United States or Taiwan. Finally, the limited number of patients enrolled in our studies prevents us from assessing the significance of a number of clinical and demographic factors on influenza susceptibility and disease severity.

Although seasonal influenza epidemics are global, regional differences in human populations can impact the number and severity of influenza cases most likely through different exposure histories to circulating and vaccine strains. Vaccine efficacy and preexisting immunity to vaccine and circulating strains should be characterized at the local, national, and global levels to achieve accurate and complete assessments of the factors that impact influenza in any year.

Acknowledgements

We would like to thank the clinical coordinators at JHMI and CGMH who were responsible for the data and sample collection. We also thank Stacey Schultz-Cherry, Victoria Meliopoulos, and the St. Jude Center of Excellence in Influenza Research and Surveillance (CEIRS) for providing the ferret antisera. We thank Deena Blumenkrantz and Robert Stenzel for providing technical assistance in growing influenza viruses and Dr. Andrew Lane for providing hNEC cultures.

Funding

This work was supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N2772201400007C (R.R., K.F.C., S.L.K and A.P.), T32 AI007417 (A.L.F.), the Richard Eliasberg Family Foundation and the Research Center for Emerging Viral Infections from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan and the Ministry of Science and Technology (MOST), Taiwan MOST 109-2634-F-182-001 (Y.N.G.).

Figure legends

Figure 1. Numbers of Influenza A virus isolates defined by clades with enrollment

dates in the two surveillance sites, Baltimore (JHMI) and Taipei (CGMH). Samples collected from patients with influenza-like illness (ILI) between week 44 2015 (starting Nov 2015) and week 16 2016 (ending April 2016) were tested for influenza A viruses (IAVs) and the IAV+ samples were subtyped and clade-defined by deep sequencing. (A) JHMI, (B) CGMH. Enrollments at week 6 of 2016 in Taipei were paused due to the Chinese New Year holidays.

Figure 2. H1N1 HA phylogenetic analysis from clinical virus isolates. Clinical nasal

pharyngeal (NP) swabs or nasal washes (NW) of IAV+ patients from Baltimore (JHMI) and Taipei (CGMH) were used to sequence the HA gene segment by deep sequencing. (A) HA phylogenetic tree representing the 2015-16 H1N1 viruses from individuals at Baltimore (red) and Taipei (blue) along with the 2015-16 vaccine strain A/California/7/2009 (green) and the 2017-18 vaccine strain A/Michigan/45/2015 (green). Representative isolates for serology assays and growth analysis are highlighted in yellow. (B) Numbers of clinical virus isolates in clades 6B.1, 6B.2 and 6B were identified. (C) HA protein structure of the clade 6B.1 and 6B.2 viruses are shown on a H1 HA crystal structure of H1N1 virus (PDB:3LZG) using PyMOL. Antigenic sites Sa, Sb, Ca1, Ca2, and Cb are indicated [46]. Amino acids are used to defined 6B.1 (purple) and 6B.2 (pink) and other amino acid differences compared with A/California/7/2009 (dark green) are indicated. Enlarged 6B.2 head shows that aa173 (in pick spheres) is not on the surface of HA, and is under site Ca1 (in sticks). (D) Viruses isolated from

individuals at both Baltimore and Taipei were propagated on hNECs. Multistep growth curves were performed on hNECs at 32°C with the representative viral isolates: clade 6B.1 virus from Baltimore and of clade 6B.1, 6B.2, and 6B viruses from Taipei. Representative data from 2 independent experiments are shown. Dotted line indicates limit of detection.

Figure 3. Baseline human serum neutralizing antibody titers to vaccine and circulating strains of H1N1. Human serum was collected at the time of enrollment and neutralizing antibody (nAb) titers to the vaccine strain A/Cal/7/09, and representative circulating strains 6B.1, 6B.2, and 6B were determined by neutralization assay. (A) Baseline neutralizing antibody titers from individuals at Taipei (CGMH) (n=46) and Baltimore (JHMI) (n=45), (B) vaccinated individuals (n=22) and unvaccinated individuals (n=23) from Baltimore, and (C) vaccinated individuals (n=7) and unvaccinated individuals (n=39) from Taipei.

Figure 4. Human and ferret serum reactivity to H1N1 vaccines strains. Human serum was collected at the time of enrollment and neutralizing antibody (nAb) titers to the H1N1 vaccine strains A/Cal/7/09 and A/Mich/45/15 were determined by neutralization assay. (A) nAb titers to A/Mich/45/15 from vaccinated (n=22) and unvaccinated (n=23) individuals from Baltimore (JHMI) and vaccinated (n=7) and unvaccinated (n=39) individuals from Taipei (CGMH). To compare the baseline nAb titers between vaccine strains A/Cal/7/09 and A/Mich/45/15, individual baseline nAb titers to A/Mich/45/15 and A/Cal/7/09 in vaccinated and unvaccinated individuals from

Baltimore and Taipei were plotted (B). Male ferrets were infected with either A/Baltimore/0026/2016 (n=2) or A/Linkou/0029/2015 (n=2) and 21 days later serum was collected to determine the neutralizing antibody responses to A/Cal/7/09 and 6B.1, 6B.2, and 6B circulating viruses (C). The individual ferret serum neutralizing antibody responses to the A/Cal/7/09 virus as compared to the circulating strains (6B.1, 6B.2, 6B) was then plotted (D).

Supplementary Figure 1. Univariate analysis of baseline neutralizing antibody titers based on estimated birth year. Each individual's baseline neutralizing antibody titers to the A/Cal/7/09, 6B, 6B.2, and 6B.1 viruses were plotted against their estimated birth year. Individuals from both sites (A), individuals from Baltimore (JHMI) (B) and individuals from Taipei (CGMH) (C) are represented. Correlation analysis was performed and no significant correlations were observed.

Supplementary Figure 2. Univariate analysis of gender differences in baseline neutralizing antibody titers. Baseline neutralizing antibody titers to the A/Cal/7/09, 6B, 6B.2, and 6B.1 viruses were evaluated in individuals from Baltimore (JHMI) and Taipei (CGMH) and data were stratified by gender. Data were first stratified by gender alone (A) and then further stratified based on both gender and vaccine status (B).

References

1. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. *Nat Rev Microbiol* **2018**; 16:60.
2. Paules C, Subbarao K. Influenza. *Lancet* **2017**; 390:697-708.
3. vom Steeg LG, Klein SL. SeXX Matters in Infectious Disease Pathogenesis. *PLoS Pathog* **2016**; 12:e1005374.
4. Vermillion MS, Klein SL. Pregnancy and infection: using disease pathogenesis to inform vaccine strategy. *NPJ Vaccines* **2018**; 3.
5. World_Health_Organization. Weekly epidemiological record Nos. 51/52. Vol. 91, **2016**:601-24.
6. Davlin SL, Blanton L, Kniss K, et al. Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine. *MMWR Morb Mortal Wkly Rep* **2016**; 65:567-75.
7. Taiwan_CDC. Taiwan Influenza Express 2015-16 Flu Season 2016 Week 20. Available at: <https://www.cdc.gov.tw/En/File/Get/VCNkIvtTOiuP1vo1gIG89A>.
8. Chambers C, Skowronski DM, Sabaiduc S, et al. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. *Euro Surveill* **2016**; 21:30168.
9. Komissarov A, Fadeev A, Sergeeva M, et al. Rapid spread of influenza A(H1N1)pdm09 viruses with a new set of specific mutations in the internal genes in the beginning of 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation). *Influenza Other Respir Viruses* **2016**; 10:247-53.
10. Ursin RL, Liu H, Powell HR, et al. Differential Antibody Recognition of H3N2 Vaccine and Seasonal Influenza Virus Strains Based on Age, Vaccine Status, and Sex in the 2017-2018 Season. *J Infect Dis* **2020**; 222:1371-82.
11. Zhou B, Donnelly ME, Scholes DT, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza A viruses. *Journal of virology* **2009**; 83:10309-13.
12. Blumenkrantz DR, Mehoke T, Shaw-Saliba K, et al. Identification of H3N2 NA and PB1-F2 genetic variants and their association with disease symptoms during the 2014-15 influenza season. *bioRxiv* **2020**:2020.02.20.956979.
13. Fischer WA, 2nd, King LS, Lane AP, Pekosz A. Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells. *Vaccine* **2015**; 33:4495-504.
14. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. *Journal of virology* **1999**; 73:9679-82.
15. McCown MF, Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. *Journal of virology* **2005**; 79:3595-605.
16. Klein EY, Blumenkrantz D, Serohijos A, et al. Stability of the Influenza Virus Hemagglutinin Protein Correlates with Evolutionary Dynamics. *mSphere* **2018**; 3.
17. Broberg E, Melidou A, Prosenc K, et al. Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. *Euro Surveill* **2016**; 21.

18. Santos KC, Silva DB, Sasaki NA, Benega MA, Garten R, Paiva TM. Molecular epidemiology of influenza A(H1N1)PDM09 hemagglutinin gene circulating in Sao Paulo State , Brazil: 2016 anticipated influenza season. *Rev Inst Med Trop Sao Paulo* **2017**; 59:e9.
19. European_Centre_for_Disease_Prevention_and_Control. Influenza virus characterisation summary Europe, May 2016. Available at: <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/influenza-virus-characterisation-may-2016.pdf>.
20. Bedford T, Neher R. Seasonal influenza circulation patterns and projections for 2016-2017. Available at: <https://github.com/nextstrain/static/blob/master/content/reports/01-flu-vaccine-selection/03-2016-september.md>.
21. Altman MO, Angel M, Košík I, et al. Hemagglutinin Glycan Clock Guides Human Influenza A Virus Evolution. *bioRxiv* **2017**.
22. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. *Eur J Pharm Biopharm* **2015**; 94:251-63.
23. Blanton L, Wentworth DE, Alabi N, et al. Update: Influenza Activity - United States and Worldwide, May 21-September 23, 2017. *MMWR Morb Mortal Wkly Rep* **2017**; 66:1043-51.
24. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. *Methods Mol Biol* **2012**; 865:147-62.
25. Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. *Arch Intern Med* **2008**; 168:2405-14.
26. Clark AM, DeDiego ML, Anderson CS, et al. Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins. *PloS one* **2017**; 12:e0188267.
27. Uda K, Shoji K, Koyama-Wakai C, et al. Clinical characteristics of influenza virus-induced lower respiratory infection during the 2015 to 2016 season. *J Infect Chemother* **2018**; 24:407-13.
28. Zhao XN, Zhang HJ, Li D, et al. Whole-genome sequencing reveals origin and evolution of influenza A(H1N1)pdm09 viruses in Lincang, China, from 2014 to 2018. *PloS one* **2020**; 15:e0234869.
29. Blanton L, Alabi N, Mustaquim D, et al. Update: Influenza Activity in the United States During the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine. *MMWR Morb Mortal Wkly Rep* **2017**; 66:668-76.
30. European_Centre_for_Disease_Prevention_and_Control. Influenza virus characterisation, summary Europe, June 2017: Stockholm: ECDC, **2017**.
31. Neher RA, Bedford T. nextflu: real-time tracking of seasonal influenza virus evolution in humans. *Bioinformatics* **2015**; 31:3546-8.
32. Bedford T, Neher R. Seasonal influenza circulation patterns and projections for 2017-2018. Available at: <https://nextflu.org/reports/feb-2017/>.
33. Pebody R, Warburton F, Ellis J, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. *Euro Surveill* **2016**; 21.
34. Korsun N, Angelova S, Gregory V, Daniels R, Georgieva I, McCauley J. Antigenic and genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2016 season. *Infect Genet Evol* **2017**; 49:241-50.

35. Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE. Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain. *Vaccine* **2018**; 36:4095-101.
36. Raymond DD, Stewart SM, Lee J, et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. *Nat Med* **2016**; 22:1465-9.
37. Liu F, Tzeng WP, Horner L, et al. Influence of Immune Priming and Egg Adaptation in the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses After Influenza Vaccination in Adults. *J Infect Dis* **2018**; 218:1571-81.
38. World_Health_Organization. Recommended composition of influenza virus vaccines for use in the 2017 southern hemisphere influenza season. Available at: https://www.who.int/influenza/vaccines/virus/recommendations/2017_south/en/.
39. World_Health_Organization. Recommended composition of influenza virus vaccines for use in the 2017- 2018 northern hemisphere influenza season. Available at: https://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/.
40. Linderman SL, Chambers BS, Zost SJ, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. *Proceedings of the National Academy of Sciences of the United States of America* **2014**; 111:15798-803.
41. Flannery B, Smith C, Garten RJ, et al. Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. *J Infect Dis* **2018**; 218:189-96.
42. Skowronski DM, Chambers C, Sabaiduc S, et al. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada. *J Infect Dis* **2017**; 216:1487-500.
43. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. *Clin Infect Dis* **2016**; 63:21-32.
44. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. *Int J Obes (Lond)* **2012**; 36:1072-7.
45. Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination strategies. *J Infect Dis* **2014**; 209 Suppl 3:S114-9.
46. Krause JC, Tumpey TM, Huffman CJ, et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. *Journal of virology* **2010**; 84:3127-30.

Figure 1

Figure 2

A

Vaccine strains

References

Collection sites:

Baltimore

Taipei

6B.1

B

Clade	Baltimore (n=26)	Taipei (n=53)
6B.1	24 (92.3%)	30 (56.6%)
6B.2	0 (0%)	20 (37.7%)
6B	2 (7.7%)	3 (5.7%)

6B

6B.2

6B

C

D

Figure 3

A

B

C

Figure 4

A

B

C

D

Supplementary Figure 1

medRxiv preprint doi: <https://doi.org/10.1101/2020.10.05.20203042>; this version posted October 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Supplementary Figure 2

A

B

Table 1. Patient characteristics at the two geographic locations, Baltimore and Taipei.

		Baltimore			Taipei		
		ILI+, IAV+	ILI+, IAV-	p-value	ILI+, IAV+	ILI+, IAV-	p-value
Age							
	18-49	70.6% (60/85)	64.7% (108/167)	0.3973	62.2% (92/148)	68.0% (66/97)	0.501
	50-64	23.5% (20/85)	26.9% (45/167)	0.6483	25.0% (37/148)	24.7% (24/97)	1
	65+	5.9% (5/85)	8.4% (14/167)	0.6166	12.8% (19/148)	7.2% (7/97)	0.2048
Race							
	White	23.5% (20/85)	40.1% (67/167)	0.0114	0% (0/148)	0% (0/97)	1
	Black or African American	67.1% (57/85)	54.5% (91/167)	0.0594	0% (0/148)	0% (0/97)	1
	Asian	0% (0/85)	1% (1/167)	1	100% (148/148)	100% (97/97)	1
	Other	9.4% (8/85)	4.8% (8/167)	0.1765	0% (0/148)	0% (0/97)	1
Gender							
	Female	52.9% (45/85)	57.5% (96/167)	0.5051	65.5% (97/148)	52.6% (51/97)	0.0461
	Male	47.1% (40/85)	42.5% (71/167)		34.5% (51/148)	47.4% (46/97)	
Vaccination							
	Vaccinated	29.8% (25/84)	50.3% (82/163)	0.0028	6.1% (9/148)	12.4% (12/97)	0.1037
Co-morbidities							
	None	35.3% (30/85)	19.8% (33/167)	0.0089	54.7% (81/148)	47.4% (46/97)	0.2392
	One	29.4% (25/85)	29.9% (50/167)	1	20% (29/148)	29% (28/97)	
	Multiple	35.3% (30/85)	50.3% (84/167)	0.0319	25.7% (38/148)	23.7% (23/97)	
Pregnancy		6.7% (3/45)	3.2% (3/95)	0.3861	5.2% (5/97)	5.9% (3/51)	1
Disease severity							
	Oxygen supplementation	17.6% (15/85)	28.7% (48/167)	0.0648	23.0% (34/148)	17.5% (17/97)	0.3374
	Intubation	0% (0/84)	0% (0/167)	1	1% (1/148)	3% (3/97)	0.3033
	Inpatient	29.4% (25/85)	44.3% (74/167)	0.0288	31% (46/148)	44% (43/97)	0.0584
	Length of stay	3 (1-12)	2 (1-21)	0.8824	5 (1-55)	6 (1-59)	0.8476
	ICU	8.0% (2/25)	0% (0/74)	0.0618	4.3% (2/46)	7.0% (3/43)	0.6729
	Pneumonia	18% (15/85)	28% (46/167)	0.1528	41% (60/148)	40% (39/97)	1
	Death	0% (0/85)	0% (0/167)	1	4% (6/148)	0% (0/97)	0.0839

Table 2. Clinical and demographic characteristics of H1N1 IAV-infected patients at Baltimore and Taipei

		H1N1		
		Baltimore	Taipei	p value
Age				
	18-49	79.5% (31/39)	75.0% (48/64)	0.64
	50-64	17.9% (7/39)	20.3% (13/64)	1
	65+	2.6% (1/39)	4.7% (3/64)	1
Race				
	White	10.3% (4/39)	0% (0/64)	0.0186
	Black or African American	74.4% (29/39)	0% (0/64)	<0.0001
	Asian	0% (0/39)	100% (64/64)	<0.0001
	Other	15.4% (6/39)	0% (0/64)	0.0023
Gender				
	Female	48.7% (19/39)	65.6% (42/64)	0.1022
	Male	51.3% (20/39)	34.4% (22/64)	
Vaccination				
	Vaccinated	31.6% (12/38)	4.7% (3/64)	0.0004
Co-morbidities				
	None	38.5% (15/39)	60.9% (39/64)	0.0414
	One	33.3% (13/39)	22% (14/64)	0.2496
	Multiple	28.2% (11/39)	17.2% (11/64)	0.2194
Pregnancy		10.5% (2/19)	0% (0/42)	<0.0001
Disease severity				
	Oxygen supplementation	12.8% (5/39)	9.4% (6/64)	1
	Intubation	0% (0/39)	0% (0/64)	1
	Inpatient	23.1% (9/39)	19% (12/64)	0.4286
	Length of stay	3 (1-12)	6 (3-9)	0.2256
	ICU	11.1% (1/9)	0% (0/12)	0.45
	Pneumonia	18% (7/39)	34% (22/64)	0.1149
	Death	0% (0/39)	2% (1/64)	1

Table 3. Allen-Cady multivariate analysis

Model 1: A/Cal/7/09					
Variable	Coefficient	95% CI		p-Value	Coefficient
Age	-0.03	-0.04	-0.01	0.00	-0.04
Vaccination	2.01	1.48	2.54	0.00	1.82
Education	-0.78	-1.31	-0.26	0.00	-1.06
Male	-0.50	-0.99	-0.02	0.04	
Asian					
Employment					-0.99
BMI					
Steroid usage					-2.03
Vaccination by PSW	2.14	1.12	3.17	0.00	1.63
Vaccination x Asian**	2.08	0.88	3.28	0.00	3.50

*Education: college or higher, BMI: Body mass index

** Effect modification between antibody titers, vaccination and Asian; adjusted for age and

Model 2: 6B			Model 3: 6B.1			
95% CI		p-Value	Coefficient	95% CI		p-Value
-0.07	-0.01	0.00	-0.03	-0.06	0.00	0.02
0.95	2.70	0.00				
-1.97	-0.15	0.02	-1.03	-1.90	-0.17	0.02
			-1.02	-1.83	-0.22	0.01
			-2.56	-3.36	-1.76	0.00
-1.92	-0.06	0.04				
-3.98	-0.07	0.04				
0.32	2.94	0.01	1.14	-0.19	2.47	0.00
1.71	5.30	0.00	2.70	0.76	4.64	0.01

d education in model 1; age, education, steroid usage and employment in model 2; male, education

Model 4: 6B.2			
Coefficient	95% CI		p-Value
-0.04	-0.06	-0.02	0.00
2.20	1.44	2.97	0.00
-0.04	-0.09	0.00	0.05
2.63	0.69	4.58	0.01
0.52	-1.15	2.19	0.54

n in model 3; and BMI, chills and HIV or AIDS in model

Supplementary Table 1: Influenza A virus strains and associated GenBank accession numbers

Strain name	HA clade	GenBank accession no.
A/Baltimore/0008/2016	6B.1	KY487698
A/Baltimore/0026/2016	6B.1	KY950126
A/Baltimore/0065/2016	6B.1	KY950052
A/Baltimore/0076/2016	6B.1	KY487689
A/Baltimore/0077/2016	6B.1	KY950108
A/Baltimore/0088/2016	6B	KY487140
A/Baltimore/0091/2016	6B.1	KY615553
A/Baltimore/0092/2016	6B.1	KY487543
A/Baltimore/0096/2016	6B.1	KY615388
A/Baltimore/0097/2016	6B.1	KY487190
A/Baltimore/0101/2016	6B.1	KY487503
A/Baltimore/0103/2016	6B.1	KY487506
A/Baltimore/0104/2016	6B.1	KY487646
A/Baltimore/0107/2016	6B.1	KY487472
A/Baltimore/0110/2016	6B.1	KY615408
A/Baltimore/0117/2016	6B.1	KY487377
A/Baltimore/0118/2016	6B.1	KY615604
A/Baltimore/0122/2016	6B.1	KY615559
A/Baltimore/0124/2016	6B.1	KY487575
A/Baltimore/0125/2016	6B.1	KY487453
A/Baltimore/0158/2016	6B.1	KY487430
A/Baltimore/0163/2016	6B.1	KY487592
A/EastBaltimore/0103/2016	6B	KY487656
A/EastBaltimore/0107/2016	6B.1	KY487123
A/EastBaltimore/0119/2016	6B.1	KY615447
A/EastBaltimore/0141/2016	6B.1	KY487527
A/Keelung/0011/2015	6B.1	KY487251
A/Keelung/0013/2015	6B.1	KY949643
A/Keelung/0027/2016	6B.2	KY487340
A/Keelung/0029/2016	6B.1	KY487499
A/Keelung/0031/2016	6B.2	KY615480
A/Keelung/0038/2016	6B.2	KY487655
A/Keelung/0039/2016	6B.1	KY949887
A/Keelung/0042/2016	6B.2	KY487695
A/Keelung/0046/2016	6B.1	KY487149
A/Keelung/0053/2016	6B.1	KY487727
A/Keelung/0055/2016	6B.1	KY950148

A/Keelung/0056/2016	6B.1	KY487617
A/Keelung/0065/2016	6B.2	KY487219
A/Keelung/0068/2016	6B.1	KY615443
A/Linkou/0004/2015	6B.1	KY950124
A/Linkou/0029/2015	6B.2	KY950184
A/Linkou/0030/2015	6B	KY949802
A/Linkou/0032/2015	6B.1	KY949823
A/Linkou/0034/2015	6B	KY949991
A/Linkou/0039/2015	6B.1	KY949680
A/Linkou/0046/2016	6B.1	KY949679
A/Linkou/0047/2016	6B.2	KY949975
A/Linkou/0049/2016	6B.1	KY950223
A/Linkou/0050/2016	6B.2	KY949736
A/Linkou/0057/2016	6B.1	KY615390
A/Linkou/0060/2016	6B.2	KY615424
A/Linkou/0065/2016	6B.1	KY487702
A/Linkou/0068/2016	6B.1	KY615570
A/Linkou/0077/2016	6B.2	KY487687
A/Linkou/0084/2016	6B.2	KY487767
A/Linkou/0093/2016	6B.1	KY487613
A/Linkou/0097/2016	6B.1	KY615425
A/Linkou/0098/2016	6B.1	KY615441
A/Linkou/0099/2016	6B.1	KY487353
A/Taipei/0008/2015	6B.2	KY487478
A/Taipei/0015/2015	6B.1	KY487273
A/Taipei/0018/2016	6B.1	KY487725
A/Taipei/0021/2015	6B.1	KY487147
A/Taipei/0025/2016	6B.2	KY487209
A/Taipei/0030/2016	6B.1	KY487336
A/Taipei/0032/2016	6B.2	KY487330
A/Taipei/0037/2016	6B.2	KY487649
A/Taipei/0040/2016	6B.1	KY487744
A/Taipei/0045/2016	6B	KY487602
A/Taipei/0046/2016	6B.1	KY487436
A/Taipei/0050/2016	6B.2	KY487591
A/Taipei/0054/2016	6B.1	KY487403
A/Taipei/0055/2016	6B.2	KY487233
A/Taipei/0056/2016	6B.1	KY615515
A/Taipei/0059/2016	6B.2	KY615586
A/Taipei/0061/2016	6B.1	KY487248
A/Taipei/0063/2016	6B.2	KY487365

A/Taipei/0067/2016

6B.2

KY487709

Supplementary Table 2. Clinical and demographic characteristics of H1N1 IAV-infected patients at Baltimore and Taipei based on HA clade

	Baltimore 6B.1	Taipei 6B.1	Taipei 6B.2	p-value Baltimore 6B.1 v. Taipei 6B.1	p-value Taipei 6B.1 v. Taipei 6B.2
Age					
18-49	83.3% (20/24)	80.0% (24/30)	65.0% (13/20)	1	0.3266
50-64	12.5% (3/24)	13.3% (4/30)	35.0% (7/20)	0.1572	0.5062
65+	4.2% (1/24)	6.7% (2/30)	0% (0/20)	1	0.5102
Race					
White	4.2% (1/24)	0% (0/30)	0% (0/20)	0.4444	1
Black or African American	75.0% (18/24)	0% (0/30)	0% (0/20)	<0.0001	1
Asian	0% (0/24)	100% (30/30)	100% (20/20)	<0.0001	1
Other	20.8% (5/24)	0% (0/30)	0% (0/20)	0.0134	1
Gender					
Female	54.2% (13/24)	66.7% (20/30)	75.0% (15/20)	0.4075	0.7536
Male	45.8% (11/24)	33% (10/30)	25.0% (5/20)		
Vaccination					
Vaccinated	26.1% (6/23)	6.7% (2/30)	5.0% (1/20)	0.065	1
Co-morbidities					
None	41.7% (10/24)	66.7% (20/30)	45.0% (9/20)	0.0987	0.1535
One	25.0% (6/24)	17% (5/30)	40% (8/20)	0.5104	0.1004
Multiple	33.3% (8/24)	16.7% (5/30)	15.0% (3/20)	0.2056	1
Pregnancy	7.7% (1/13)	0% (0/20)	0% (0/15)	<0.0001	1
Disease severity					
Oxygen supplementation	8.3% (2/24)	0% (0/30)	15.0% (3/20)	0.1929	0.05
Intubation	0% (0/24)	0% (0/30)	0% (0/20)	1	1
Inpatient	16.7% (4/24)	13% (4/30)	20% (4/20)	1	0.6974
Length of stay	3 (1-12)	6 (3-9)	7 (4-9)	0.7143	0.8571
ICU	0% (0/4)	0% (0/4)	0% (0/4)	1	1
Pneumonia	8% (2/24)	20% (6/30)	35% (7/20)	0.2771	0.3266
Death	0% (0/24)	0% (0/30)	0% (0/20)	1	1